European Journal of Biomedical and Pharmaceutical Sciences

ASSESSMENT OF ANTI THROMBIN III LEVEL IN SUDANESE PATIENTS WITH CHRONIC LIVER DISEASES

Mawdda Abdel Rhman Mohmed Elhassan Ahmed* and Amira Ahmed Khalid Humeida

ABSTRACT

Background: The liver is an important organ that synthesizes coagulation factors, liver disease is associated with a complex hemostasis defect, in which platelets, coagulation, and fibrinolysis may all be affected. In patients with hepatic parenchymal disease, the loss of functional parenchyma, results in decreased synthesis of both coagulation factors and natural anticoagulant proteins. The levels of coagulation factors and natural anticoagulant proteins synthesized in the liver are valuable in diagnosis and treatment, as they reflect the degree of hepatocyte damage. Recently, many studies have reported that the plasma concentrations of natural anticoagulants, such as antithrombin III (AT III), are altered in chronic liver diseases (CLD). In addition, the changes in synthesis of AT III occur in liver tissue and are associated with the extent of chronic hepatitis and cirrhosis. This study aimed to assess AT III level among chronic liver disease Sudanese patients and correlating it’s correlation with age, gender, type and duration of disease among cases and controls. Materials and Methods: This was a prospective case-control hospital-based study conducted to assess AT. III level among CLD Sudanese patients. Seventy (70) CLD patients were recruited as cases, and 30 healthy people were recruited as control group. This study was conducted at Ibn sina hospital in Khartoum, Sudan from April to August 2017. All statistical analyses were performed by SPSS software version (20). Results: In this study, the decrease of AT III level among cases than controls was the most important findings. Mean level of AT III among cases was within the lower normal limit (80-110 g\dl); (81.83 g\dl), 19 (27.1%) of cases their AT. III was lower than 80 g/dl. It had positive correlation with S. Albumin (p=.000) and negative correlation with duration of disease (P=.037) and both T. Bilirubin and D. Bilirubin (P= .041), (P=.010), respectively. Conclusion: This study concluded that; there was a strong effect of CLD on AT III level in plasma and this effected was correlated with duration of CLD and both S. Albumin and Bilirubin.

Keywords: AT III level, chronic liver disease.